Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →
logo
Get CLEATUS

Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is soliciting R33 grant applications to support the advanced development and rigorous validation of emerging technologies aimed at advancing cancer research and clinical care. This opportunity is intended for projects that have already addressed major feasibility barriers, as demonstrated by strong preliminary data, but require further refinement, optimization, and technical validation to achieve broad adoption within the scientific community. The focus is on technologies with new or substantially improved capabilities for measuring, analyzing, modeling, or interrogating cancer-related biological systems, including advanced molecular and cellular platforms, multi-omic and spatial profiling methods, next-generation imaging and sensing tools, immuno-engineering approaches, and innovations in biospecimen handling and quality assessment. Proposals must center on cancer-specific applications, and applications that merely apply established technologies to novel biological questions without technological innovation are not eligible. This funding opportunity is part of the NCI’s Innovative Molecular Analysis Technologies Program and explicitly prohibits clinical trials. The goal is to accelerate progress in areas such as cancer biology, early detection, diagnosis, treatment, control, and epidemiology by enabling technologies that offer transformative potential for the research community. Projects must demonstrate clear potential for widespread utility in cancer research while maintaining a tight focus on technical advancement rather than application-specific hypotheses. All applications must be submitted through the designated grants portal, and inquiries should be directed to the IMAT Program Contact provided. The opportunity was posted in July 2026 and is open to applicants seeking to bridge the gap between initial innovation and scalable adoption in cancer science.

General Info

NCI seeks R33 grants to advance and validate innovative cancer technologies with proven feasibility and broad research potential.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(0)

No documents available

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressUSA
Contacts
IMAT Program Contact
contact@example.gov
+1 (555) 000-0000

Full Description

Show more

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies for cancer research or clinical care. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development, enhancements, optimizations, and rigorous technical validation to encourage adoption by the research community.

Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. Projects that are in-scope include technologies with new or significantly improved technical capabilities to measure, analyze, model, or interrogate cancer-related systems. These may include, but are not limited to, advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. Technologies proposed for development may have potential for widespread applicability but must be focused in this proposal on cancer applications. Projects proposing application of existing technologies where the novelty resides in the clinical target or biological question being pursued are not appropriate for this solicitation. 

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. 

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
CUSTOM INDUCIBLE KNOCKIN MOUSE
Solicitation # PCA-NIDDK-02527
The National Institutes of Health intends to award a firm-fixed-price purchase order to Ingenious Targeting Laboratory Inc. for the creation of a custom inducible knockin mouse. This specific requirement involves an endogenous Gcm2 genomic modification, which distinguishes it from generic CRISPR/Cas9 mouse generation or services using heterologous promoters in a transgene. Based on market research, Ingenious Targeting Laboratory Inc. has been identified as the only responsible source capable of meeting these precise technical specifications. While this notice is not a request for competitive quotes, the government allows small businesses to submit written capability statements to demonstrate their ability to perform the requirement. Responses must be submitted to the primary point of contact by 9:00 a.m. EDT on September 1, 2026. If no other capable vendors are identified, the award is expected to be issued approximately five days after the notice date.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 4 days
View Details
NAICS: 541714
New
SBIR / STTR
Autonomous Navigation & Control Systems DevelopmentThe Defense Advanced Research Projects Agency under the U.S. Department of Defense is seeking a subcontract for the development of autonomous navigation and control systems. The project focuses on the design and simulation of navigation algorithms specifically for underwater vehicles operating in GPS-denied environments, utilizing a combination of acoustic, inertial, and environmental sensing technologies. This opportunity is designated as a Total Small Business Set-Aside under the SBIR/STTR mandate for companies with fewer than 500 employees, falling under NAICS code 541714. The solicitation was posted on August 26, 2026, with a response deadline of September 23, 2026.
Defense Advanced Research Projects Agency

POSTED

2 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Federal
AN41--Intent to Sole Source - Duke University MRI Service
Solicitation # 36C24626Q0986
The Department of Veterans Affairs Network Contracting Office 6, Durham VA Health Care System, intends to enter into a sole source procurement with Duke University for neuroimaging and data analytics services. This action falls under NAICS 541714 for Research and Development in Biotechnology and is being conducted under the authority of FAR 6.302-1 and FAR 12.102. Interested parties must submit their capabilities and interest to the designated contract specialist by 10:00 AM EST on August 31, 2026. The procurement strictly prohibits the use of gray market or remanufactured items, requiring all medical supplies, equipment, and maintenance services to be provided by an Original Equipment Manufacturer or an authorized dealer. Vendors must provide verification of their authorization to ensure that OEM warranties and services are maintained. Failure to comply with these requirements regarding gray market items will be considered a breach of contract, granting the government the right to terminate the agreement or require the replacement of non-compliant items at no cost.
246-NETWORK Contracting Office 6 (36C246)

POSTED

2 days ago

DEADLINE

in 3 days
View Details
NAICS: 541714
New
Federal
Preclinical Assessment of Naloxone Adequacy to Reverse Polysubstance Use-Induced Respiratory Depression — In Vivo Validation
Solicitation # 75F40126Q00382
The U.S. Food and Drug Administration is issuing a sole source, firm-fixed-price contract to Charles River Laboratories for a twelve month preclinical study. The research aims to evaluate the efficacy of naloxone and alternative reversal agents in treating respiratory depression caused by polysubstance use, specifically addressing the prevalence of fentanyl adulterated with xylazine, d-methamphetamine, or alprazolam. The study will utilize male CD rats to simultaneously measure respiratory and cardiovascular changes, as these systems are closely linked during drug-induced respiratory failure. The project consists of a four-phase in vivo study involving surgically instrumented animals. Key tasks include using whole body plethysmography for respiratory monitoring and implanted telemetry for continuous cardiovascular data collection. The contractor is responsible for collecting blood samples at five prespecified time points for pharmacokinetic analysis to be performed by the FDA. All work will be conducted in an AAALAC-accredited facility under non-GLP conditions, with statistical analysis performed via ANOVA.
FDA Office Of Acq Grant Svcs

POSTED

2 days ago

DEADLINE

in 13 days
View Details
NAICS: 541714
New
SBIR / STTR
Universal Cell Culture Platform for Rapid Establishment of Species-Agnostic Cell Lines and Autonomous Culture Operations
Solicitation # DPA26BZ05-DV020
Defense Advanced Research Projects Agency

POSTED

2 days ago

DEADLINE

in 26 days
View Details
NAICS: 541714
New
Grant
Clinical Research with Human SubjectsThe Department of Defense, through the Defense Health Agency Contracting Activity, is seeking a subcontractor for the design and execution of clinical research involving human subjects or human biospecimens. The scope of work encompasses critical research operations, including ensuring IRB compliance, managing participant recruitment, overseeing data management, and maintaining strict adherence to PHS inclusion standards. This opportunity is categorized under NAICS code 541714 and was posted on August 26, 2026. Interested parties must submit their responses by the deadline of November 4, 2026.
Defense Health Agency Contracting Activity - Dhaca

POSTED

3 days ago

DEADLINE

in 2 months
View Details
NAICS: 541714
New
SBIR / STTR
SBIR: UC-RAPID
Solicitation # DPA26BZ05-DV020
The SBIR UC-RAPID solicitation, issued by the Department of Defense Small Business Projects Office, seeks the development and demonstration of an automated, species-agnostic cell culture platform. This technology is intended to rapidly establish viable cell lines, including induced pluripotent stem cells, from a variety of non-model species to support the validation of genetic-biocontrol technologies. This opportunity is a total small business set-aside for companies with fewer than 500 employees. The solicitation was posted on August 26, 2026, with a response deadline of September 23, 2026.
Small Business Projects Office

POSTED

3 days ago

DEADLINE

in 25 days
View Details
NAICS: 541714
New
Federal
Notice of Intent to Sole Source - Gut Microbiome DNA Sequencing Services
Solicitation # 1232SA26Q1371
The Department of Agriculture, specifically the USDA Ars Afm Apd, has issued a special notice of intent to sole source a contract for Gut Microbiome DNA Sequencing Services under solicitation number 1232SA26Q1371. This procurement falls under NAICS code 541714 and is not subject to any specific set-aside restrictions. The notice was posted on August 25, 2026, with a response deadline of September 1, 2026. The place of performance is located in Pennsylvania, and the primary point of contact for this opportunity is Frank Palmer.
USDA Ars Afm Apd

POSTED

3 days ago

DEADLINE

in 4 days
View Details
NAICS: 541714
New
Federal
Firefox Proposers Day
Solicitation # DARPA-SN-26-112
The Biological Technologies Office of DARPA is hosting an in-person Proposer Day on September 1, 2026, at the DARPA Conference Center in Arlington, Virginia, to support the upcoming Firefox Program solicitation. The event runs from 9:00 AM to 5:00 PM Eastern Daylight Time and is mandatory for attendance, with no virtual options available. Each organization is limited to three attendees, and advance registration is required with a deadline of August 21, 2026. The solicitation number is DARPA-SN-26-112, and it falls under NAICS code 541714, indicating research and development in the physical, engineering, and life sciences. Proposers are directed to contact Dr. Pedro Irazoqui at Firefox@darpa.mil for inquiries, and all times referenced in the announcement and registration materials are in Eastern Daylight Time.
Defense Advanced Research Projects Agcy

POSTED

3 days ago

DEADLINE

in 14 days
View Details
NAICS: 541714
New
Federal
Local Technical Support and Installation ServicesThis subcontract involves the on-site installation, calibration, and integration of the Opentrons Flex system for the National Oceanic and Atmospheric Administration within the Department of Commerce. The scope of work includes comprehensive system validation and user training to ensure the equipment is fully operational at the federal research laboratory located in zip code 20746. The opportunity was posted on August 24, 2026, with a response deadline of September 8, 2026. Classified under NAICS code 541714, the project focuses on providing specialized local technical support and installation services to facilitate the successful deployment of the laboratory system.
National Oceanic And Atmospheric Administration

POSTED

4 days ago

DEADLINE

in 11 days
View Details
NAICS: 541714
New
SBIR / STTR
Export-Controlled Technology Development (ITAR/EAR Compliance)This subcontract opportunity with the U.S. Army under the Department of Defense focuses on research and development involving export-controlled technologies. The project requires strict adherence to ITAR and EAR regulations, specifically regarding the acquisition of necessary licenses and the proper disclosure of foreign nationals involved in the work. The opportunity is a total small business set-aside under NAICS code 541714, specifically mandated for SBIR/STTR participants with fewer than 500 employees. Interested parties must submit their responses by September 11, 2026, at 4:00 PM.
U.S. Army

POSTED

4 days ago

DEADLINE

in 14 days
View Details
NAICS: 541714
New
Federal
AN13--Intent to sole source - Miniaturized CO2 Sensor Prototype Development and Novel Physiologic Gas Monitoring Research
Solicitation # 36C24E26Q0110
The Department of Veterans Affairs RPO-E R&D intends to award a sole source Firm Fixed Price contract to the University of Michigan for the development of a miniaturized CO2 sensor prototype and research into novel physiologic gas monitoring. This notice serves as a public announcement of the intent to sole source under specific federal acquisition regulations and is not a request for proposals or quotations. Interested parties may submit capability information to demonstrate their ability to meet the requirements described in the statement of work by 10:00am EST on September 8, 2026. The government will review these submissions solely to determine if a competitive procurement is necessary. All inquiries and capability statements must be emailed to Contracting Officer Renee Kale, as telephone inquiries will not be accepted.
Rpo East (36C24E)

POSTED

4 days ago

DEADLINE

in 11 days
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 541715
New
Grant
Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes (R34 - Clinical Trial Optional)The National Institute on Minority Health and Health Disparities within the National Institutes of Health is issuing a forecast for planning grants titled Innovative Research to Improve Native Hawaiian and Pacific Islander (NHPI) Health Outcomes. These grants are designed to support preparatory, feasibility, and pilot activities that advance intervention development or solutions-oriented etiologic studies. A mandatory requirement for all projects is that they must be co-developed with community partners to ensure the effectiveness of the health outcomes being addressed. Priority areas for funding include formative studies on understudied contributors to chronic diseases like cancer and diabetes, as well as the adaptation and pilot-testing of interventions for maternal and infant health. Additionally, the program seeks feasibility and acceptability testing for strategies aimed at reducing behavioral risk factors, such as poor nutrition and smoking, to promote sustained behavior change and measurable improvements in health for NHPI populations.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

4 days ago

DEADLINE

N/A
View Details
NAICS: 334510
New
Grant
Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources (S15 Clinical Trial Not Allowed)The National Institutes of Health, under the Department of Health and Human Services, has issued a forecast for the Small Instruments and Modern Equipment for Shared-use Biomedical Research Facilities and Resources program. This funding opportunity is designed for eligible shared biomedical research facilities, such as core facilities, biorepositories, and model resource facilities, to acquire new small instruments or scientific equipment. The primary objective is to enhance the operational efficiency and capabilities of resources shared by multiple researchers. Priority is given to requests for small instruments utilizing emerging technologies or those that generate physical, chemical, or biomaterial outputs rather than standard digital data. It is important to note that funding is restricted and cannot be used for building-level infrastructure or highly specialized instruments that only indirectly support research. Clinical trials are not allowed under this specific opportunity.
Electromedical and Electrotherapeutic Apparatus Manufacturing

POSTED

5 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Phase 2The National Institutes of Health, through the National Institute on Drug Abuse, is forecasting Phase 2 of the Single Cell Opioid Responses in the Context of HIV (SCORCH) program. This initiative builds upon Phase 1 research by utilizing single-nucleus datasets from human and animal postmortem brain tissue to investigate the interactions between Substance Use Disorder and HIV disease progression within the Central Nervous System. The program aims to employ advanced single cell approaches, including the study of RNA splicing, epigenomic features, and spatial interactions, to conduct both data mining and hypothesis-driven research. The ultimate goal is to enhance the mechanistic understanding of how these conditions affect the brain at subcellular and circuit levels to identify potential targets for novel therapeutic interventions.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Translational Research in Maternal and Pediatric Pharmacology and TherapeuticsThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to issue a Notice of Funding Opportunity for translational research in maternal and pediatric pharmacology and therapeutics. This initiative aims to improve safe and effective precision therapeutics for pregnant women, lactating women, infants, children, and adolescents. The program focuses on advancing precision medicine via novel tools and technologies, developing safer therapeutics, improving patient-provider communication regarding drug safety, and scaling evidence-based interventions. This forecast is part of the agency's stewardship of the Best Pharmaceuticals for Children Act and recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. While the project outlines clear goals for enhancing medication effectiveness and safety across these specific patient populations, applications are not currently being solicited. Interested parties can coordinate with the Obstetric and Pediatric Pharmacology and Therapeutics Branch for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC)The Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) is a legislatively mandated Centers of Excellence program managed by the National Institutes of Health under the Department of Health and Human Services. This initiative focuses on expanding and intensifying basic, translational, and clinical research regarding muscular dystrophy through interdisciplinary collaboration and shared resources. By supporting innovative center-based projects and providing robust training environments for emerging scientists, the program aims to achieve research outcomes that exceed the capabilities of stand-alone grants. A critical component of the program is its commitment to patient-centered research, actively engaging patient and advocacy communities to increase awareness and ensure that study designs are informed by patient perspectives. This forecast opportunity is supported by several grant authorities, including 42 U.S.C. 281, 283g, 285g, and 284h. Interested parties can coordinate with the NICHD Intellectual and Developmental Disabilities Branch for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes (U01- Clinical Trials Not Allowed)The National Institutes of Health, through the National Institute of Diabetes and Digestive and Kidney Diseases, is seeking a coordinated, milestone-driven research project titled Multimodal AI to Accelerate Precision Medicine for Type 1 Diabetes. This initiative aims to integrate large, longitudinal, and multimodal datasets from various T1D research consortia to examine how different biological processes, tissues, and organs interact to drive the development and progression of the disease. By combining human pancreas and clinical data, the project seeks to uncover new insights into T1D biology, identify biomarkers, and inform personalized approaches for prevention and treatment. To achieve these goals, the project will focus on the development and testing of advanced multimodal AI models and AI-enabled research workflows. Key technical objectives include creating new methods for data integration and generating privacy-preserving synthetic datasets. This effort is designed to move beyond the limitations of individual studies to provide a comprehensive understanding of the different forms and stages of Type 1 Diabetes, ultimately accelerating the advancement of precision medicine.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

9 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Established Clinician Investigator Award to Support Mentoring (KS1)The Established Clinician Investigator Award to Support Mentoring (KS1) is a forecast opportunity issued by the National Institutes of Health under the Department of Health and Human Services. This award is designed to provide established clinician investigators with a sustained period of protected time, enabling them to deliver high-quality mentoring and guidance to early-career clinician research scientists. The program is managed by the Division of Biomedical Research Workforce, which serves as the primary point of contact for interested parties. While specific performance locations and set-aside details are not listed, the award aims to strengthen the pipeline of clinician researchers through structured mentorship support.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure – Clinical Coordinating Center (CCC) and Data Coordinating Center (DCC)The National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute, is seeking to provide continued support for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). This initiative focuses on conducting clinical trials to improve outcomes for patients experiencing non-stroke neurological and cardiovascular emergencies within pre-hospital or emergency department settings by identifying effective early-stage treatments. The program specifically seeks to establish a Clinical Coordinating Center (CCC) and a Data Coordinating Center (DCC) to support the network's infrastructure. While this notice serves as a forecast to allow potential applicants time to form collaborations and prepare responsive applications, formal solicitations are not currently being accepted.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 611430
Grant
Mentored Career Transition Award (KT1/R00)The Mentored Career Transition Award (KT1/R00), issued by the National Institutes of Health under the Department of Health and Human Services, is a biphasic grant designed to transition postdoctoral researchers into independent, tenure-track faculty roles. The award provides up to five years of total support, beginning with a mentored career development phase lasting one to two years. The second phase offers up to three years of independent research funding, which is contingent upon the recipient's satisfactory progress during the initial phase and the procurement of an approved, research-intensive faculty position. This forecasted opportunity is managed by the Division of Biomedical Research Workforce.
Professional and Management Development Training

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 621910
Grant
Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN) Infrastructure – Clinical Enrollment HubsThe National Institutes of Health, through the National Institute of Neurological Disorders and Stroke and the National Heart, Lung and Blood Institute, is seeking to support the infrastructure for the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN). This initiative focuses on establishing clinical enrollment hubs to conduct trials aimed at improving outcomes for individuals experiencing non-stroke neurological and cardiovascular emergencies within pre-hospital or emergency department settings. This notice serves as a forecast to allow potential applicants time to establish collaborations and develop responsive applications. While the program aims to identify effective early-stage treatments, applications are not currently being solicited. Interested parties can contact the NINDS Department of Emergency Medicine for further information.
Ambulance Services

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541714
Grant
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)The National Institute on Aging is issuing a forecast for the Alzheimer's Drug-Development Program to support the pre-clinical and early-stage clinical Phase I development of novel biologic and small-molecule drug candidates. The program aims to identify treatments that prevent Alzheimer's disease, slow its progression, or address cognitive and behavioral symptoms. Funding is available for academic and biotech researchers to conduct development activities internally or through specialized contract research organizations. The initiative focuses on expanding the portfolio of investigational drug candidates for emerging therapeutic targets and diversifying the therapeutic pipeline to support mono-therapy, combination therapy, and precision medicine approaches. This opportunity will utilize the U01 activity code. While applications are not currently being accepted, this notice serves to allow potential applicants time to establish collaborations and design responsive projects.
Research and Development in Biotechnology (except Nanobiotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details
NAICS: 541715
Grant
Mentored Research Scientist Career Development Award (KR1)The Mentored Research Scientist Career Development Award (KR1), issued by the National Institutes of Health under the Department of Health and Human Services, is designed to support candidates with research doctoral degrees in their pursuit of future research independence. The award provides up to five years of protected time for intensive career development under the guidance of an experienced mentor. This opportunity is currently listed as a forecast with a posted date of August 13, 2026. Interested parties can contact the Division of Biomedical Research Workforce via email at nihtrain@mail.nih.gov for further information.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

16 days ago

DEADLINE

N/A
View Details